Oxamate, an LDHA Inhibitor, Inhibits Stemness, Including EMT and High DNA Repair Ability, Induces Senescence, and

Takuma Hashimoto1, Go Ushikubo1, Naoya Arao1

  • 1Laboratory of Radiation Biology, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.

Insights

Oxamate enhances glioblastoma radiosensitivity by inhibiting DNA repair and promoting cell death. This glycolysis inhibitor also reduces cancer stem cell properties and epithelial-mesenchymal transition, offering potential for improved glioblastoma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Enhanced glycolysis is linked to tumor cell stemness and malignant phenotypes.
  • Glioblastoma cells exhibit increased glycolysis, contributing to their aggressive nature.

Purpose of the Study:

  • To investigate the effects of Oxamate, a glycolysis inhibitor, on radiosensitivity in T98G glioblastoma cells.
  • To elucidate the molecular mechanisms underlying Oxamate's impact on glioblastoma radiosensitivity.

Main Methods:

  • T98G glioblastoma cells were treated with Oxamate and subjected to irradiation.
  • Analysis included DNA repair assessment (γ-H2AX foci), apoptosis and senescence assays (SA-β-gal, pS15-p53, p21), and evaluation of EGFR, stem cell, and EMT markers.

Main Results:

  • Oxamate significantly enhanced radiosensitivity by delaying DNA repair.
  • Oxamate induced apoptosis and cellular senescence.
  • Oxamate downregulated EGFR, reduced stem cell markers, and modulated EMT markers, suggesting suppression of EMT.

Conclusions:

  • Oxamate enhances glioblastoma radiosensitivity via multiple mechanisms, including DNA repair inhibition, apoptosis/senescence induction, and suppression of stemness and EMT.
  • Oxamate shows potential as a radiosensitizer for glioblastoma therapy, warranting further clinical investigation.